Spots Global Cancer Trial Database for Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Official Title: A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

Study ID: NCT03184571

Conditions

Lung Cancer Metastatic

NSCLC Stage IV

Adenocarcinoma of Lung

Interventions

Bemcentinib; pembrolizumab

Study Description

Brief Summary: This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in up to 106 participants with previously treated, advanced adenocarcinoma of the lung. The study will enroll three cohorts of participants with previously treated, advanced adenocarcinoma of the lung: Cohort A will consist of participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will consist of participants who received a maximum of one prior line of an anti-programmed death receptor (PD)-(L)1 therapy (monotherapy). Cohort C will consist of participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.The primary objective is to assess the anti-tumor activity of bemcentinib and pembrolizumab when given in combination.

Detailed Description: